Patents Examined by Dennis Heyer
  • Pharmaceutical compositions comprising meloxicam
    Patent number: 10537642
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: January 21, 2020
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Pharmaceutical compositions comprising meloxicam
    Patent number: 10532101
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: January 14, 2020
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Solid forms of bendamustine hydrochloride
    Patent number: 10517852
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: December 31, 2019
    Assignee: Cephalon, Inc.
    Inventors: Martin Ian Cooper, Laurent D. Courvoisier, Mark Eddleston, Robert E. McKean
  • Pharmaceutical compositions comprising meloxicam
    Patent number: 10517950
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: December 31, 2019
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Pharmaceutical compositions comprising meloxicam
    Patent number: 10512692
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: December 24, 2019
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Pharmaceutical compositions comprising meloxicam
    Patent number: 10512693
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: December 24, 2019
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Methods and compositions for bowel cleansing before a medical procedure
    Patent number: 10507217
    Abstract: Described are kits, food compositions and methods for cleaning the bowel, e.g., in preparation for a medical procedure, e.g., a diagnostic or treatment procedure, such as an endoscopic or surgical procedure, or radiologic imaging such as CT colography.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: December 17, 2019
    Assignee: The General Hospital Corporation
    Inventors: Joshua Korzenik, Corey A. Siegel, Douglas Knuth
  • Methods of treating opiate dependency and preventing non-oral opiate abuse among opiate addicts
    Patent number: 10507205
    Abstract: The present invention relates to the use of an inseparable combination of morphine and at least one opiate antagonist with a bioavailability of less than 5% on oral administration for producing a medicament to be administered orally for treatment of opiate dependency in humans and to the use of an inseparable combination of an opiate and at least one opiate antagonists with a bioavailability of less than 5% on oral administration for producing a medicament to be administered orally for prevention of non-oral opiate abuse in opiate addicts.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: December 17, 2019
    Assignee: Purdue Pharmaceutical Products L.P.
    Inventor: Lars Hermann
  • Method for differentially diagnosing ACTH-dependent Cushing's syndrome
    Patent number: 10495650
    Abstract: This invention provides for an improved method for differentially diagnosing ACTH-dependent Cushing's syndrome. Current practice for differentially diagnosing ectopic ACTH syndrome and Cushing's Disease measures relative ACTH concentrations from the inferior petrosal venous sinus compared to fluid obtained from a periphery venous sample. This is performed before and after administration of exogenous corticotropin releasing factor, or after administration of metyrapone. This invention uses glucocorticoid receptor antagonists to induce release of endogenous CRH which stimulates ACTH to increase in patients with ectopic ACTH syndrome but not in those with Cushing's Disease.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: December 3, 2019
    Assignee: Corcept Therapeutics, Inc.
    Inventor: Andreas G. Moraitis
  • Stable aqueous capsaicin injectable formulations and medical uses thereof
    Patent number: 10493047
    Abstract: The invention provides stable, aqueous capsaicin injectable formulations, a unit dose containing such injectable formulations, medical kits, and methods for using such injectable formulations and unit doses to treat patients suffering from pain, such as osteoarthritic knee pain. The stable, aqueous capsaicin injectable formulations may contain, for example, capsaicin, a solubilizing agent (e.g., a polyethylene glycol ester of a (C15-C25) hydroxyalkanoic acid), an antioxidant, and water.
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: December 3, 2019
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Drazen Ostovic, Gary Fred Musso
  • Pharmaceutical compositions comprising meloxicam
    Patent number: 10485871
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as pain.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: November 26, 2019
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Oral formulations of pyrrolidine derivatives
    Patent number: 10478420
    Abstract: The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one-O-methyloxime, and/or an active metabolite thereof, and the use of said formulations in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea and embryo implantation failure due to uterine contractions. The present invention is furthermore related to processes for their preparation.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: November 19, 2019
    Assignee: ObsEva S.A.
    Inventors: Andre Chollet, Oliver Pohl
  • Pharmaceutical compositions comprising meloxicam
    Patent number: 10463736
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability, solubility, or pharmacokinetics of the NSAID for the treatment of conditions such as pain.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: November 5, 2019
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Method for treating a neurovascular complication of diabetes mellitus
    Patent number: 10463632
    Abstract: A method of preventing and/or treating a disease caused by diabetes complications includes administering to a patient in need thereof, an effective amount of thymoquinone or a pharmaceutically acceptable salt thereof, either singly or in combination with a pharmaceutically acceptable carrier, diluent or excipient. The disease can be at least one of retinopathy, nephropathy, neuropathy, and neurological disorder.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: November 5, 2019
    Assignee: King Saud University
    Inventors: Khalid Mohammed Alkharfy, Ghulam Mohammad, Ajaz Ahmad, Mohammad Mairaj Siddiquei, Ahmed Abu El-Asrar
  • Stable crystal form of tipiracil hydrochloride and crystallization method for the same
    Patent number: 10457666
    Abstract: Crystal Form I of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione hydrochloride exhibiting powder X-ray peaks at two or more angles selected from the group consisting of 11.6°, 17.2°, 17.8°, 23.3°, 27.1°, and 29.3° as a diffraction angle (2?±0.2°).
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: October 29, 2019
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Hideki Kazuno, Tomonobu Mutsumi
  • Pharmaceutical composition comprising betahistine
    Patent number: 10456386
    Abstract: The present disclosure relates to a pharmaceutical composition comprising as active substance betahistine or a pharmaceutically acceptable salt thereof, for use in the treatment of otological or neurological disorders in a human subject by intranasal application.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: October 29, 2019
    Assignee: OTOLANUM AG
    Inventors: Christopher John Wraight, Thomas Meyer
  • Pharmaceutical compositions comprising meloxicam
    Patent number: 10456471
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability, solubility, or pharmacokinetics of the NSAID for the treatment of conditions such as pain.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: October 29, 2019
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Systems and methods for treating cancer
    Patent number: 10449197
    Abstract: Embodiments of the invention provide a method of treating cancer, the method comprising providing a subject having cancer cells, and contacting the cancer cells with a therapeutically effective amount of a G2/M checkpoint inhibitor. Embodiments of the invention also provide a method of treating cancer in a subject, the method comprising the steps of: (a) receiving a sample of the cancer cells from the subject; (b) determining if at least a portion of the sample of the cancer cells is LKB 1 deficient; and (c) contacting the cancer cells with a therapeutically effective amount of a G2/M checkpoint inhibitor.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: October 22, 2019
    Assignees: Dignity Health, The Translational Genomics Research Institute
    Inventors: Timothy G. Whitsett, Jr., Landon J. Inge
  • 2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors
    Patent number: 10450285
    Abstract: The invention relates to a compound of general formula (I): wherein R1, R2, R3, R4, Q, m and n are as defined herein. The compounds are inhibitors of Bcl3 and are useful for the treatment of cancer, particularly metastatic cancer.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: October 22, 2019
    Assignee: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED
    Inventors: Andrew David Westwell, Andrea Brancale, Richard William Ernest Clarkson, Jitka Soukupova
  • Methods for treating pulmonary hypertension
    Patent number: 10441590
    Abstract: The present invention provides a method of using arylpiperazine derivatives for treating pulmonary hypertension. The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: October 15, 2019
    Assignee: Reviva Pharmaceuticals, Inc.
    Inventors: Laxminarayan Bhat, Marc Cantillon, Ellen M. Wallis, Seema Rani Bhat